27.12 USD
▲-2.13+3.83%
盘后 26.12 0.00%
2026-08-03
市值
$3.46B
市盈率
—
EPS
-2.31
股息率
—
52 周区间
3.76 – 31.35
成交量
754.35K
Beta
-0.67
目标价
40.11
52W 低 3.7652W 高 31.35
价格走势
公司简介
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment of neuroinflammatory and neurodegenerative diseases. It also develops lonigutamab, a monoclonal antibody targeting IGF-1R for the treatment of thyroid e...